VA Prepares for Possible FDA Approval of Psychedelic Therapies

A senior adviser at the Veterans Health Administration said this month that as many as 2.1 million veterans with conditions like post-traumatic stress disorder (PTSD) or depression could be candidates for psychedelic therapies, but cautioned that the VA would likely treat only “four digits worth of patients” in the first year after any FDA approval as it manages supply and safety. No psychedelic drug is currently FDA-approved to treat mental illness; ketamine is the only psychedelic-like drug approved for medical use. Following an April executive order to accelerate research and access, FDA granted fast-track reviews to three developers.